• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications.
BackgroundPertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). However, alternative chemotherapy partners are required(More)
521Background: In APHINITY (NCT01358877), adding P to H + C significantly improved invasive disease-free survival in pts with HER2-positive EBC (von Minckwitz, NEJM 2017). Pt-reported health-related(More)
Background: First-line (1L) docetaxel+trastuzumab+pertuzumab (THP) is approved for HER2-positive metastatic breast cancer (MBC), based on superior progression-free (PFS) and overall survival vs TH in(More)